Cytek Biosciences
CTKB
5.43
+0.07
+1.31%
Cytek Biosciences
US · CTKB
#3522 by market cap
Listed 2021
5.43
+0.07
+1.31%
Live - 5344 symbols - heartbeat 112s ago
· 2026-10-09 19:30
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.19, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +0.52% YoY
Margins
- Gross margin
- 51.84%
- Operating margin
- -20.04%
- Net margin
- -33.02%
Key ratios & quality
- Enterprise valuei
- 453.98M
- Altman Z-Scorei
- 4.19
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 57.88M | 92.84M | 127.95M | 164.04M | 193.02M | 200.45M | 201.49M |
| Gross profit | 28.67M | 51.71M | 79.14M | 100.97M | 109.43M | 111.11M | 104.46M |
| Selling & admin expenses | 16.98M | 24.36M | 45.55M | 67.92M | 93.12M | 92.23M | 108.38M |
| Research & development | 8.93M | 13.69M | 24.44M | 34.86M | 44.15M | 39.40M | 36.47M |
| Operating profit | 2.76M | 13.66M | 9.16M | -1.80M | -27.85M | -20.52M | -40.38M |
| Pretax profit | -16.29M | 14.43M | 5.94M | 1.26M | -15.71M | -5.70M | -29.84M |
| Tax | 533.00K | -4.98M | 2.91M | -1.22M | -3.56M | 320.00K | 36.70M |
| Net profit | -16.83M | 19.41M | 3.03M | 2.48M | -12.15M | -6.02M | -66.54M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Diluted EPS | -0.16 | 0.09 | 0.00 | 0.02 | -0.09 | -0.05 | -0.52 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 41.46M | 45.60M | 52.29M | 62.14M | 44.14M | 48.14M |
| Gross profit | 20.16M | 23.87M | 27.55M | 32.89M | 21.25M | 28.34M |
| Selling & admin expenses | 25.41M | 25.67M | 27.79M | 29.52M | 30.11M | 30.00M |
| Research & development | 9.73M | 8.83M | 8.96M | 8.96M | 9.60M | 9.74M |
| Operating profit | -14.98M | -10.62M | -9.19M | -5.59M | -18.46M | -11.40M |
| Pretax profit | -11.27M | -6.78M | -7.77M | -4.03M | -17.37M | -11.64M |
| Tax | 136.00K | -1.19M | -2.29M | 40.05M | 1.49M | 515.00K |
| Net profit | -11.40M | -5.58M | -5.48M | -44.08M | -18.87M | -12.16M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.09 | -0.04 | -0.04 | -0.34 | -0.15 | -0.09 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 67.77M | 208.62M | 431.73M | 454.02M | 392.06M | 396.45M | 392.00M |
| Cash & ST investments | 30.12M | 165.23M | 364.62M | 341.15M | 262.41M | 277.86M | 261.53M |
| Inventory | 18.43M | 23.02M | 32.17M | 48.15M | 60.88M | 43.89M | 48.43M |
| Total assets | 70.36M | 219.98M | 463.31M | 519.48M | 494.46M | 499.50M | 461.54M |
| Total current liabilities | 21.04M | 26.54M | 33.18M | 49.04M | 56.23M | 67.66M | 77.80M |
| Short-term debt | -- | 2.77M | -- | 3.51M | 3.01M | 8.41M | 9.18M |
| Long-term debt | -- | -- | -- | 2.27M | 1.65M | 1.05M | 525.00K |
| Total liabilities | 112,062,000.00 | 236,007,000.00 | 57,920,000.00 | 93,930,000.00 | 101,393,000.00 | 103,763,000.00 | 119,803,000.00 |
| Total equity | -41.70M | -16.03M | 405.39M | 425.55M | 393.06M | 395.74M | 341.74M |
| Retained earnings | -42.02M | -22.61M | -19.61M | -17.03M | -29.18M | -35.20M | -101.74M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 380.50M | 382.83M | 388.49M | 392.00M | 379.30M | 377.93M |
| Cash & ST investments | 265.61M | 262.02M | 261.73M | 261.53M | 262.23M | 262.00M |
| Inventory | 45.35M | 49.49M | 51.65M | 48.43M | 49.79M | 52.25M |
| Total assets | 482.60M | 493.32M | 494.92M | 461.54M | 449.11M | 446.93M |
| Total current liabilities | 67.69M | 73.27M | 75.21M | 77.80M | 80.94M | 84.34M |
| Short-term debt | 7.53M | 8.77M | 10.68M | 9.18M | 13.66M | 12.70M |
| Long-term debt | 918.00K | 791.00K | 655.00K | 525.00K | 386.00K | 246.00K |
| Total liabilities | 102,973,000.00 | 115,763,000.00 | 116,348,000.00 | 119,803,000.00 | 121,469,000.00 | 124,980,000.00 |
| Total equity | 379.62M | 377.56M | 378.57M | 341.74M | 327.64M | 321.95M |
| Retained earnings | -46.60M | -52.18M | -57.66M | -101.74M | -120.60M | -132.76M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.75M | 15.16M | 4.63M | -12.23M | 5.28M | 25.38M | -4.69M |
| Depreciation & amortization | 309.00K | 603.00K | 1.24M | 5.66M | 9.23M | 10.49M | 11.98M |
| Free cash flow | -14.72M | 13.61M | 266.00K | -22.10M | 454.00K | 21.65M | -8.88M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 215.69M | 0 | -44.15M | -21.61M | -15.07M |
| Ending cash balance | 30.49M | 166.12M | 364.62M | 299.50M | 167.63M | 98.75M | 90.85M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -125.00K | 108.00K | -3.90M | -771.00K | -2.74M | 1.37M |
| Depreciation & amortization | 2.88M | 2.99M | 3.06M | 3.04M | 2.81M | 2.99M |
| Free cash flow | -976.00K | -1.54M | -4.55M | -1.80M | -4.94M | -877.00K |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -10.63M | -4.51M | 29.00K | 34.00K | 0 | 0 |
| Ending cash balance | 95.30M | 75.47M | 93.28M | 90.85M | 65.67M | 73.85M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | 0.00 | 0.62 | -2.97 | -1.53 | -18.05 |
| ROA %i | -23.92 | 13.37 | 0.00 | 0.52 | -2.40 | -1.21 | -13.85 |
| ROIC %i | -- | -- | 0.64 | 0.22 | -3.65 | -3.46 | -17.45 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -4.38 |
| EBIT margin %i | -28.15 | 15.90 | 6.00 | 2.34 | -7.07 | -10.24 | -14.57 |
| FCF / sales %i | -- | 14.66 | 0.21 | -- | 0.24 | 10.80 | -- |
| Current ratioi | 3.22 | 7.86 | 13.01 | 9.26 | 6.97 | 5.86 | 5.04 |
| Quick ratioi | 2.28 | 6.91 | 11.88 | 7.99 | 5.67 | 5.00 | 4.29 |
| Debt / assetsi | -- | 1.26 | 0.00 | 3.48 | 2.86 | 3.41 | 5.14 |
| LT debt / equityi | -- | -- | -- | 3.43 | 2.83 | 2.17 | 4.26 |
| Interest coveragei | -16,293.00 | 44.33 | 4.41 | 1.49 | -6.59 | -- | -61.96 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 41.51 | 27.63 | 16.14 | 7.10 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -67.81 | 333.37 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -2.91 | -1.67 | -3.36 | -18.05 | -20.93 | -23.04 |
| ROA %i | -2.31 | -1.31 | -2.60 | -13.85 | -15.89 | -17.14 |
| ROIC %i | -4.68 | -3.41 | -4.80 | -17.45 | -20.04 | -21.89 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -11.64 | -11.35 | -15.14 | -14.57 | -17.39 | -19.59 |
| FCF / sales %i | 8.80 | 5.51 | -- | -- | -- | -- |
| Current ratioi | 5.62 | 5.22 | 5.17 | 5.04 | 4.69 | 4.48 |
| Quick ratioi | 4.74 | 4.35 | 4.30 | 4.29 | 3.94 | 3.71 |
| Debt / assetsi | 3.29 | 4.80 | 5.02 | 5.14 | 6.12 | 5.92 |
| LT debt / equityi | 2.20 | 3.95 | 3.74 | 4.26 | 4.22 | 4.27 |
| Interest coveragei | -- | -- | -- | -61.96 | -79.78 | -129.82 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Product is the largest reported line at 67.63% of revenue, across 2 reported segments.
- Service follows at 32.37%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Product67.63%
Service32.37%
Quote time 2026-10-09 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Cytek Biosciences discussion 0 comments